Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trifarotene sails through 52-week acne trial

Key clinical point: A novel retinoid cream proved safe and effective for moderate truncal and facial acne in a year-long study.

Major finding: About 58%of patients who treated their moderate facial and truncal acne with trifarotene cream for 1 year achieved a score of 0 or 1 – clear or almost clear – with at least a 2-grade improvement from baseline by Investigator’s Global Assessment at both acne sites.

Study details: This was a 52-week, multicenter study of once-daily, open-label trifarotene cream in 454 patients with moderate facial as well as truncal acne.

Disclosures: The presenter reported serving as a paid investigator for and consultant to Galderma, the study sponsor.

Citation:

Del Rosso JQ. AAD 2020, Abstract 13882.